Revance Investors Ink $17M Deal In Take-Private Offer Suit
By Sydney Price · March 23, 2026, 7:51 PM EDT
Dermal fillers company Revance Therapeutics Inc. and two of its executives have agreed to a $17 million settlement to end claims the company hurt investors after the value of a take-private...
To view the full article, register now.